FGF21 and fatty liver disease: A meta-analysis published in 2017 suggested that FGF21 showed excellent performance to distinguishing NASH from hepatic steatosis and it performed well in identifying NASH; however, its ability to confirm the diagnosis was inadequate due to the fact that the number of studies included was very few (this biomarker was modestly sensitive and specific, with pooled values of 62 and 78%, respectively) (81, 82).